Pathogenetic, clinical and pharmaco-economic assessment in rheumatoid arthritis (RA)

Internal and Emergency Medicine

Volumn 6, Issue , 2011, Pages S11-S15

  Ferraccioli, Gianfranco ^a   Gremese, Elisa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

B cells Remission; Cost saving; Early rheumatoid arthritis; TH17

Indexed keywords

ARTICLE; COST CONTROL; HUMAN; PATHOLOGY; PHARMACOECONOMICS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

ARTHRITIS, RHEUMATOID; COST SAVINGS; ECONOMICS, PHARMACEUTICAL; HUMANS; QUESTIONNAIRES;

EID: 84857091397     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0668-6     Document Type: Article

References (31)

1. Plenge RM (2009) Rheumatoid arthritis genetics: 2009 update. Curr Rheumatol Rep 11:351–356
2. Tolusso B, Frezza D, Mattioli C, Fedele AL, Bosello S, Faustini F, Peluso G, Giambra V, Pietrapertosa D, Morelli A, Gremese E, De Santis M, Ferraccioli GF (2009) Allele *2 of the HS1, 2 A enhancer of the Ig regulatory region associates with rheumatoid arthritis. Ann Rheum Dis 68:416–419
3. Orozco G, Eyre S, Hinks A, Bowes J, Morgan AW, Wilson AG, Wordsworth P, Steer S, Hocking L, UKRAG consortium, Worthington J, Barton A (2011) Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 70:463–468
4. Ria F, Penitente R, De Santis M, Nicolo’ C, Di Sante G, Orsini M, Arzani D, Fattorossi A, Battaglia A, Ferraccioli GF (2008) Collagen-specific T cell repertoire in blood and synovial fluid varies with disease activity in early rheumatoid arthritis. Arthritis Res Therapy 10:R135
5. De Rosa MC, Giardina B, Bianchi C, Carelli Alinovi C, Pirolli D, Ferraccioli GF, De Santis M, Di Sante G, Ria F (2010) Modeling the ternary complex TCR-Vbeta/Collagen II (261–273)/HLADR4 associated with rheumatoid arthritis. PLoS ONE 5(7): e11550
6. Ria F et al. Unpublished
7. Ferraccioli GF, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F (2010) Interleukin 1 b and interleukin 6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. M O L M E D 1 6:552–557
8. Ferraccioli GF, Zizzo G (2011) The potential role of TH17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model. Discovery Medicine 11:413–424
9. Zizzo G, De Santis M, Bosello SL, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli GF (2011) Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. Clin Immunol 138:107–116
10. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, McFarlane JD (1994) Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha(cA2) in patients with rheumatoid arthritis. Lancet 344:1105–1110
11. Tanimoto K, Iwabuchi Y, Tanne Y, Kamiya T, Inubushi T, Mitsuyoshi T, Tanne K (2011) Interleukin 1 beta affects cyclooxygenase 2 expression and cartilage metabolism in mandibular condyle. Arch Oral Biol [Epub ahead of print]
12. Koshy PJ, Henderson N, Logan C, Life PF, Cawston TE, Rowan AD (2002) Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann Rheum Dis 61:704–713
13. Mihara M, Moriya Y, Kishimoto T, Ohsugi Y (1995) Interleukin 6 induces the proliferation of synovial fibroblastic cells in the presence of soluble IL6 receptors. Br J Rheumatol 34:321–325
14. Kotake S, Sato K, Kim KJ, Takahashi N, Udagawa N, Nakamura I, Yamaguchi A, Kishimoto T, Suda T, Kashiwazaki S (1996) Interleukin-6 and soluble interleukin 6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 11:88–95
15. Trebec-Reynolds DP, Voronov I, Heersche JN, Manolson MF (2010) IL1 alpha and IL1beta have different effects on formation and activity of large osteoclasts. J Cell Biochem 109:975–982
16. Rutella S, De Cristofaro R, Ferraccioli GF (2009) Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Human Immunol 70:360–373
17. Bosello S, Pers JO, Rochas C, Devauchelle V, De Santis M, Daridon C, Saraux A, Ferraccioli GF, Youinou P (2007) BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 20:1–8
18. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli GF (2008) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity and response to treatment in early rheumatoid arthritis. J Rheumatol 35:1256–1264
19. Tolusso B, De Santis M, Bosello S, Gremese E, Gobessi S, Cuoghi I, Rumi C, Efremov DG, Ferraccioli GF (2009) Synovial B cells of rheumatoid arthritis express Zap-70 which increases the survival and correlates with the inflammatory and autoimmune phenotypes. Clin Immunol 131:98–108
20. Michelutti A, Gremese E, Morassi F, Petricca L, Arena V, Tolusso B, Alivernini S, Peluso G, Bosello SL, Ferraccioli GF (2011) B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and Zap-70 and characterize the aggregate pattern irrespectively of the autoantibody status. Mol Med [Epub ahead of print]
21. Pietrapertosa D, Tolusso B, Gremese E, Papalia MC, Bosello S, Peluso G, Petricca L, Michelutti A, Faustini F, Fedele AL, Ferraccioli GF (2010) Diagnostic performance of anti-citrullinated peptide antibodies for the diagnosis of rheumatoid arthritis: the relevance of the likelihood ratios. Clin Chem Lab Med 48:829–834
22. Neogi T et al (2010) The 2010 American College of Rheumatology/European League against Rheumatism classification criteria for rheumatoid arthritis. Phase 2 methodological report. Arthritis Rheum 62:2582–2591
23. Maini RN, StClair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354:1932–1939
24. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, the CHARISMA Study Group (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817–2829
25. Van der Linden MPM, Le Cessie S, Raza K, Van der Woude D, Knevel R, Huizinga TW, Van der Helm-Van Mil AH (2010) Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 62:3537–3546
26. Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, Van Riel PL, Vam de Laar MA (2011) Implementation of a treat to target strategy in very early rheumatoid arthritis: results of the DREAM remission induction cohort. Arthritis Rheum 63 [Epub ahead of print]
27. Bosello S, Fedele AL, Peluso G, Gremese E, Tolusso B, Ferraccioli GF (2011) Very early rheumatoid arthritis is the major predictor of major outcomes: clinical ACR remission and radiographic non-progression. Ann Rheum Dis 70:1292–1295
28. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, Ferraccioli GF (2011) Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis 70:172–175
29. Kobelt G (2006) Health economic issues in rheumatoid arthritis. Scand J Rheumatol 35:415–425
30. Emery P, Breedvel FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen MD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382
31. Wolfe F, Michaud K, Choi HK, Williams R (2005) Household income and earnings losses among 6,396 persons with rheumatoid arthritis. J Rheumatol 32:1875–1883